Victoria Hentschke
Victoria studied Molecular Biosciences at the University of Göttingen and Heidelberg. She joined Springer in 2013 and is now Journal Development Editor of open access journals in the field of clinical neurology.
European Headache Federation guidelines for the use of monoclonal antibodies in migraine prevention: from evidence to recommendations
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor are a new preventive treatment for migraine, acting upon one of the molecules implied in the pathogenesis of migraine headache. The European Headache Federation has recently published their guideline on the use of these monoclonal antibodies for migraine prevention. We have invited junior headache researcher Raffaele Ornello to explain the main findings and why they are important.
© ustas / stock.adobe.com
What is the aim of the guideline and what is the European Headache Federation (EHF) hoping to achieve for patients and physicians?
Several trials have tested the efficacy and safety of the new anti-CGRP monoclonal antibodies. The aim of the guideline was to summarize the available evidence and provide patients and physicians with indications for treatment with anti-CGRP monoclonal antibodies just before their commercialization.
.png)
No hay comentarios:
Publicar un comentario